THE UBIQUITOUS DISTRIBUTION OF ET-1 AND ITS RECEPTORS IMPLICATES ITS INVOLVEMENT IN A WIDE VARIETY OF PHYSIOLOGIC AND PATHOLOGIC PROCESSES IN THE BODY.

image4

DIABETES AND OTHER ENDOCRINE DISORDERS

ET-Traps Limited  lead indication is to treat diabetes, both type-1 and type-2, a group of metabolic disorders characterized by high blood sugar levels over a prolonged period. Symptoms of high blood sugar include frequent urination, increased thirst and increased hunger. If left untreated, diabetes can cause many complications. Acute complications can include diabetic ketoacidosis, hyperosmolar hyperglycemic state, or death. Serious long-term complications include cardiovascular disease, stroke, chronic kidney disease, foot ulcers, and damage to the eyes.  Currently available therapies are mainly limited to glucose control medications and medications to treat the disease complications and hence, do not prevent progression of disease that is linked to the irreversible damage to the vital organs.

The ET-traps approach to diabetes provides therapeutic synergy for (i) bringing back the pathologically elevated levels of endothelin-1 and (ii) repair of damage caused to the vital organs (long-term complications).

If you or someone you know has been newly diagnosed, please find clear and informative information about the condition here.


Please note, diabetes is more than just high glucose. Click here to find out more. 



We established our PoC in the diabetes disease space. However, elevated/ pathological levels of endothelin-1 are also found in the following diseases:

CARDIOVASCULAR DISEASES

  • atherosclerosis
  • cardiac hypertrophy
  •  ischemic heart disease
  •  heart failure
  • stroke


NEURODEGENERATIVE DISORDERS

    

  • Alzheimer's disease
  • Multiple sclerosis
  • Parkinson's disease



PREGNANCY DISORDERS

Pre-eclampsia is a pregnancy-induced hypertensive disorder characterized by proteinuria and widespread maternal endothelial dysfunction. It remains one of the most common disorders in pregnancy and remains one of the leading causes of maternal and fetal morbidity. Recent research has revealed that placental insufficiency, resulting in hypoxia and ischemia, is a central causative pathway in the development of the disorder. In response, the placenta secretes soluble substances into the maternal circulation which are responsible for the symptomatic phase of the disease. Among the most well characterized factors in the disease pathology are the anti-angiogenic protein soluble fms-like tyrosine kinase-1 (sFlt-1), inflammatory cytokines, and agonistic angiotensin II type-1 receptor autoantibodies. Each of these factors has been shown to induce hypertension experimentally through the production of endothelin-1 (ET-1), a powerful vasoconstrictor. Antagonism of the endothelin-A receptor has proved beneficial in numerous animal models of gestational hypertension, and it remains an intriguing target for pharmacological intervention in pre-eclampsia.
​



Please see following link for further information on different diseases with increased levels of endothelin-1